An Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

Trial Profile

An Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Hydroxychloroquine/ribavirin (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioLineRx
  • Most Recent Events

    • 27 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 07 May 2013 BioLineRx expects to report interim results in the fourth quarter of 2013 and final results in the first half of 2014.
    • 29 Apr 2013 Planned number of patients changed from 40 to 32, as reported in a BioLineRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top